Published in Synapse on May 01, 2000
Food reinforcement and eating: a multilevel analysis. Psychol Bull (2007) 2.32
Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology (2007) 1.68
Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav (2008) 1.33
Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol (2013) 1.22
Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther (2009) 1.17
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J (2007) 1.06
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol (2008) 1.06
Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther (2009) 1.03
Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend (2014) 1.01
Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf (2009) 0.96
Generation of serotonin neurons from human pluripotent stem cells. Nat Biotechnol (2015) 0.95
Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One (2009) 0.94
Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) (2006) 0.92
Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome(1,2,3). eNeuro (2015) 0.84
Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol (2014) 0.84
Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin. J Pharmacol Exp Ther (2015) 0.83
Nonhuman primate neuroimaging and cocaine medication development. Exp Clin Psychopharmacol (2008) 0.82
Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. Drug Alcohol Depend (2010) 0.82
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol (2013) 0.79
MSI-1436 reduces acute food intake without affecting dopamine transporter activity. Pharmacol Biochem Behav (2010) 0.78
Extending Previous cG×I Findings on 5-HTTLPR's Moderation of Intervention Effects on Adolescent Substance Misuse Initiation. Child Dev (2016) 0.75
4-methyl benzylamine stimulates food consumption and counteracts the hypophagic effects of amphetamine acting on brain Shaker-like Kv1.1 channels. Br J Pharmacol (2006) 0.75
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. J Neurophysiol (2015) 0.75
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 4.03
A proposal for the classification of sigma binding sites. Trends Pharmacol Sci (1992) 2.65
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Sigma receptors: biology and function. Pharmacol Rev (1990) 2.37
Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab (1993) 2.28
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol (2006) 2.06
Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? Science (1977) 1.77
Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology (2000) 1.72
Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther (2005) 1.70
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A (2000) 1.69
In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology (1996) 1.57
Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci (2012) 1.55
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J Med Chem (2001) 1.54
Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther (2006) 1.50
Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. J Subst Abuse Treat (1994) 1.45
Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J Med Chem (1978) 1.43
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation (1999) 1.42
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay. Synapse (2001) 1.39
Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience (2010) 1.33
Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem (1999) 1.31
SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther (1995) 1.30
Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience (2008) 1.22
Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience (2010) 1.22
Presence and formation of codeine and morphine in the rat. Proc Natl Acad Sci U S A (1986) 1.20
Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav Neurosci (2009) 1.20
Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol (2001) 1.16
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides (1990) 1.14
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. J Med Chem (1998) 1.14
Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther (2001) 1.11
Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem (1987) 1.10
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J Med Chem (1985) 1.09
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav (2006) 1.08
Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. J Comp Neurol (1987) 1.07
Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience (2010) 1.07
GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav (1991) 1.07
Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther (2001) 1.06
Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther (2007) 1.05
Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo. J Pharmacol Exp Ther (1996) 1.04
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. Mol Pharmacol (1991) 1.04
Opioid receptors on cells of the immune system: evidence for delta- and kappa-classes. J Endocrinol (1989) 1.04
Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J Pharmacol Exp Ther (2009) 1.03
A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands. Bioorg Med Chem (2000) 1.02
Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett (1989) 1.02
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res (1999) 1.02
Purification of the opiate receptor of NG108-15 neuroblastoma-glioma hybrid cells. Proc Natl Acad Sci U S A (1985) 1.02
Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats. Neuroscience (2009) 1.02
Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse (2000) 1.01
Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. J Med Chem (1998) 1.01
Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther (2010) 1.00
GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther (1994) 0.99
Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. Life Sci (1982) 0.98
A rapid, high-yield conversion of codeine to morphine. J Med Chem (1977) 0.98
Effect of beta-FNA on opiate receptor binding: preliminary evidence for two types of mu receptors. Eur J Pharmacol (1983) 0.98
Allosteric modulation by leucine-enkephalin of [3H]naloxone binding in rat brain. Eur J Pharmacol (1981) 0.98
Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J Pharmacol Exp Ther (2001) 0.98
Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology (1998) 0.98
Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Mol Psychiatry (2002) 0.96
Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther (2000) 0.96
[3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem (1985) 0.96
Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J Pharmacol Exp Ther (1996) 0.95
delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. J Med Chem (1999) 0.95
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists. J Med Chem (1998) 0.95
1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology (2001) 0.95
beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther (1988) 0.94
Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci (1997) 0.94
Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav Pharmacol (2003) 0.94
CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity. Eur J Pharmacol (1995) 0.94
Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol (1994) 0.94
Biosynthesis of viomycin. II. Origin of beta-lysine and viomycidine. Biochemistry (1974) 0.93
Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology (1992) 0.93
Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet (2008) 0.93
Receptor-selective antagonism of opioid antinociception in female versus male rats. Behav Pharmacol (2001) 0.93